Posted June 27, 2024
Gov. Ron DeSantis signed HB885 into law on June 18th, which expands patient access to biomarker testing, a key tool used by physicians to identify the most effective treatment of cancer and other diseases. In the case of a cancer diagnosis, biomarker testing allows doctors to develop a personalized treatment plan. It opens the door...
Posted June 24, 2024
Bipartisan members of the Unites States House of Representatives and Senate have reintroduced the Association for Clinical Oncology (ASCO)-endorsed Improving Seniors’ Timely Access to Care Act (H.R.8702/S.4532) to streamline prior authorization within Medicare Advantage (MA) plans. The bill currently has 175 combined cosponsors (45 senators and 130 representatives). Last Congress, this legislation unanimously passed in...
Posted March 26, 2024
On February 6, a rapid recommendation update on Capivasertib-Fulvestrant was published. The rapid update has implications for two guidelines: Endocrine Treatment and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancers and Biomarkers for Systemic Therapy in Metastatic Breast Cancer.
Posted March 26, 2024
Congress passed a six-part spending bill that funds several government agencies, including the FDA, through Sept. 30, 2024—the end of the fiscal year. The legislative package also contains a 1.68% increase to the Medicare physician reimbursement rate until Dec. 31, 2024. The increase partially reduces the 3.37% reimbursement cut that went into effect on January...
Posted March 26, 2024
Healthcare workforce and innovation were front and center during the 2024 Legislative Session, which concluded on Friday, March 8. The FMA was an active participant in shaping the future of Florida’s healthcare landscape, which can be seen through the pro-physician victories outlined in our end-of-session report.
Posted March 26, 2024
The Florida legislature passed a bill late Tuesday that expands patient access to biomarker testing, a key tool used by physicians to identify the most effective treatment of cancer and other diseases. In the case of a cancer diagnosis, biomarker testing allows doctors to develop a personalized treatment plan so patients may not have to...
Posted February 26, 2024
On February 11, a federal judge dismissed a drug industry trade group’s legal challenge to halt Medicare drug price negotiations, ruling that it lacked standing. The complaint was filed by the Pharmaceutical Research and Manufacturers of America (PhRMA), the Global Colon Cancer Association (GCCA), and the National Infusion Center Association (NICA) in June of last...
Posted February 21, 2024
February 14, 2024 marked day 30 of the 60-day Florida Legislative Session, and the FMA remains hard at work to help physicians practice medicine. This midpoint report by FMA Assistant General Counsel Mary Thomas, Esq., summarizes some of the most notable bills that could affect you and your patients, where each one stands in the...
Posted February 8, 2024
In a big win for physicians and patients, the Centers for Medicare & Medicaid Services recently released a final prior authorization and interoperability rule that makes significant improvements to the prior authorization process — most importantly, shortening the timeframes for payors to make decisions on such requests. Set to take effect in 2026, these changes...
Posted January 25, 2024
On Thursday evening, Congress passed another short-term spending bill, funding the federal government into early March. Unfortunately, the bill only extended healthcare-related policies that were included in the previous funding bill and does not include any new healthcare policies, such as an increase in the Medicare Physician Fee Schedule. The previous spending bill funded a...
© 2021 FLASCO | Premium Website Design by The HDG
